The Future of Research in PEComas
The panel shares future areas of research in malignant PEComa that interest them, and how they see the treatment landscape evolving.
Case 3: Retroperitoneal PEComa
Dr Andrew Wagner presents the case of a young man with a retroperitoneal PEComa.
Case 2: Hormone Receptor Positive Uterine PEComa
Martee Hensley, MD, presents the case of a post-menopausal woman with a hormone receptor positive malignant uterine PEComa.
Treatment Options for PEComas After Progression on Nab-Sirolimus
A review of the available treatment options for a patient with PEComa who have disease progression after nab-sirolimus.
Toxicity Management in Patients Receiving mTOR Inhibitors
A discussion on the toxicities associated with mTOR inhibitors and which patients with PEComa would be considered good candidates.
The AMPECT Trial: Nab-sirolimus in PEComa
Dr Andrew Wagner shares data from the AMPECT trial investigating the potential role of mTOR inhibitors in PEComa.
Case 1: Uterine PEComa with a TSC2 Mutation
Dr Elizabeth Davis presents the case of a young woman with a TSC2-mutated uterine PEComa.
Systemic Therapy in Malignant PEComas
Andrew Wagner, MD, PhD, details his typical treatment approach for systemic therapy in patients with malignant PEComa.
Current Treatment Landscape of PEComas
Elizabeth Davis, MD, explains the current treatment options available for patients with PEComa.
Introduction to PEComas
Andrew Folpe, MD, provides an overview of PEComas, including their incidence rate and malignant tumors.
2 Clarke Drive Cranbury, NJ 08512